PDC*line Pharma team wishes you and your loved ones a festive & healthy holiday season and a successful 2021!

Have a look at the interview of PDC*line Pharma 's CEO Eric Halioua by Andrew McConaghie a journalist of SCRIP in an on-demand "Fireside Chat" session during the BIOEUROPE FALL 2020. He presents the...

Eric Halioua, President & CEO of PDC*line Pharma will be today, Nov. 2nd 2020, a panelist in a round table on Therapeutic Cancer vaccines and make a company presentation at the Festival of Biologics v...

PDC*line Pharma, a biotech company developing a novel class of potent and off-the-shelf cancer immunotherapies to treat cancer patients, today announced that the Company will give presentations and...

Cohorts A2 (single agent high dose in adjuvant setting) and B1 (low dose added to anti-PD-1) have been opened and first patient of cohort A2 has been dosed

Liège, Belgium and Grenoble, France...

We are very pleased to announce that PDC*line Pharma is one of the three nominees for the 2020 BVA Award Venture company of the year! 

THE BELGIAN VENTURE CAPITAL & PRIVATE EQUITY ASSOCIATION...

PDC*line Pharma strengthens its board of directors with an

industry leader in the field of immuno-oncology

Liège, Belgium and Grenoble, France, June 25, 2020 – PDC*line Pharma, a clinical stage...

PDC*line Pharma is pleased to announce that Eric Halioua, PDC*line Pharm’s President & CEO, has been invited to present at 3rd Annual Next-Gen Immuno-Oncology Congress, a virtual event, will be held...

We are very pleased to announce the publication in OncoImmunology of the results of the first in-human trial with our innovative plasmacytoid dendritic cell line based cancer vaccine in melanoma...

New article and interview of our President & CEO Eric Halioua for the 2020 edition of the Belgium Healthcare & Life Science Review of the magazine PharmaBoardroom. He introduces the Belgian immuno...